Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation
Commercial intravenous immunoglobulin G (IVIG) at high doses has therapeutic benefit in autoimmune and inflammatory diseases. It has been shown to inhibit T-cell function but the mechanisms are unclear. Inhibition could result from IVIG processing, donor pooling or intrinsic downregulatory activity...
Ausführliche Beschreibung
Bibliographische Detailangaben
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 132(2009), 2 vom: 01. Aug., Seite 222-33
|
|---|
| 1. Verfasser: |
MacMillan, Heather F
(VerfasserIn) |
|---|
| Weitere Verfasser: |
Lee, Tim,
Issekutz, Andrew C |
|---|
| Format: | Online-Aufsatz
|
|---|
| Sprache: | English |
|---|
| Veröffentlicht: |
2009
|
|---|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.)
|
|---|
| Schlagworte: | Journal Article
Research Support, Non-U.S. Gov't
Antibodies, Monoclonal
CD28 Antigens
CD3 Complex
Immunoglobulin Fab Fragments
Immunoglobulin G
Immunoglobulins, Intravenous
Receptors, Antigen, T-Cell |
|---|